Advanced Prostate Cancer Management: Proceedings of a scientific session, 20-21 July 2018, Manila, Philippines

Abstract

Prostate cancer, the second most common cancer worldwide in 2012, poses a high public burden prompting the need to develop effective treatment strategies. To determine the progress made through the years, this paper documented the timeline of treatment strategies for advanced prostate cancer as presented in a scientific session held in July 2018. Two treatment strategies for metastatic prostate cancer were emphasized: the addition of docetaxel (chemotherapy) and abiraterone acetate plus prednisone to androgen-deprivation therapy (i.e. standard of care). Related clinical trials including but not limited to the CHAARTED trial, STAMPEDE trial, and LATITUDE trial showed that addition of either DOC or ABI led to a general increase in the overall survival of the patient. Furthermore, treatment strategies for non-metastatic castration resistant prostate cancer were also discussed. Evidence from clinical trials showed that addition of enzalutamide or apalutamide to ADT yielded better outcomes than ADT-placebo. These recent advancements have broadened the physician's options for treatment.